Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI South East AsiaCPhI South East Asia
Not Confirmed
Not Confirmed
16-18 July, 2025
Not Confirmed
Not Confirmed
04-07 July, 2025
Not Confirmed
Not Confirmed
07-11 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI South East AsiaCPhI South East Asia
Industry Trade Show
Not Confirmed
16-18 July, 2025
Industry Trade Show
Not Confirmed
04-07 July, 2025
Industry Trade Show
Not Confirmed
07-11 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/j-j-s-intra-cellular-buyout-bms-oncology-gambit-sanofi-s-blueprint-acquisition-drive-mega-deals-in-h1-2025
30 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250630609767/en/Sarepta-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
25 Jun 2025
// FDA
https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-deaths-due-acute-liver-failure-non-ambulatory-duchenne-muscular-dystrophy-patients
16 Jun 2025
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/sarepta-shares-tumble-second-patient-death-after-gene-therapy-treatment-2025-06-16/
16 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250614701775/en/Sarepta-Provides-Safety-Update-for-ELEVIDYS-and-Initiates-Steps-to-Strengthen-Safety-in-Non-Ambulatory-Individuals-with-Duchenne
04 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250604599467/en/U.S.-FDA-Grants-Platform-Technology-Designation-to-the-Viral-Vector-Used-in-SRP-9003-Sareptas-Investigational-Gene-Therapy-for-the-Treatment-of-Limb-Girdle-Muscular-Dystrophy-Type-2ER4
21 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250521736806/en/Sarepta-Provides-Update-on-UK-Dosing-in-ENVISION-Study-of-ELEVIDYS-for-the-treatment-of-Duchenne-Muscular-Dystrophy
ABOUT THIS PAGE
Sarepta Therapeutics is a supplier offers 2 products (APIs, Excipients or Intermediates).
Find a price of SRP-2001 DRUG SUBSTANCE bulk with DMF offered by Sarepta Therapeutics
Find a price of AVI 4126 bulk offered by Sarepta Therapeutics